Neurocrine Biosciences | NBIX - Operating Expenses


Neurocrine Biosciences reported $739.1M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Cytokinetics USD 207.8M 7.22M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Exelixis USD 380.28M 20.8M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Prothena USD 25.29M 1.94M Mar/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Repligen USD 185.01M 2.01M Sep/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Teva Pharmaceutical Industries USD 3.92B 691M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026